WuXi Biologics touted its partnerships and contracts in its annual report on Tuesday, noting that it has almost 700 projects in its pipeline, which can help supply the service provider with security.
The stocks for both WuXi Biologics and its sister company WuXi AppTec have yet to meaningfully recover since January, when the draft of the BIOSECURE Act gained momentum. “In the face of uncertainties, we are dedicated to finding certainty and stability through our strategic initiatives,” CEO Chris Chen said in a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.